[8-K] UNITED STATES ANTIMONY CORP Reports Material Event

Rhea-AI Filing Summary

United States Antimony Corporation (UAMY) reported that its Board of Directors has appointed Jon R. Marinelli as a new director, effective November 24, 2025. With his addition, the Board increases to seven members, of which five are independent, and he will also serve as Chairman of a newly formed Finance Committee.

Marinelli brings more than 25 years of experience in capital markets, M&A, and strategic advisory work, including leadership roles at BMO Capital Markets and Deutsche Bank’s natural resources group, and has advised on over $285 billion in transactions. He will serve until the next annual shareholder meeting under the company’s standard non-employee director compensation program, and there are no related-party transactions requiring disclosure.

Insights

Corporate Governance Analyst

Board expanded with an experienced finance professional and new Finance Committee, modestly strengthening oversight and governance.

The company added Jon R. Marinelli to the board on November 24, 2025, raising board size to seven, of which five are independent. He is also appointed as Chairman of a newly formed Finance Committee, signaling a more structured focus on financial matters at the board level. He will serve until the next annual meeting, under standard director terms.

Mr. Marinelli brings over 25 years in capital markets, M&A, and strategic advisory roles, with senior positions at BMO Capital Markets and Deutsche Bank’s Global Banking–Natural Resources Group. The company highlights his transaction experience across more than $285 billion in M&A, equity, and debt deals, which may enhance board-level financial and transaction oversight. His compensation will match existing non‑employee director arrangements, so this move does not introduce a new bespoke pay structure.

There are no disclosed related-party arrangements or transactions under Item 404(a), which reduces conflict-of-interest concerns. A press release dated November 25, 2025 (Exhibit 99.1) communicates the appointment but is furnished under Item 7.01, limiting Exchange Act Section 18 liability and clarifying materiality treatment. From a governance perspective, the additions of an independent director with significant financial experience and a dedicated Finance Committee are structurally favorable changes to monitor at least through the next annual meeting.

false 0000101538 UNITED STATES ANTIMONY CORP 0000101538 2025-11-24 2025-11-24 0000101538 UAMY:CommonStockOneMember 2025-11-24 2025-11-24 0000101538 UAMY:CommonStockTwoMember 2025-11-24 2025-11-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported) November 24, 2025

UNITED STATES ANTIMONY CORPORATION

(Exact name of registrant as specified in its charter)

Texas		001-08675		81-0305822
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification Number)

4438 W. Lovers Lane, Unit 100, Dallas, TX		75209
(Address of principal executive officers)		(Zip Code)

Registrant’s telephone number, including area code: (406) 606-4117

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		UAMY		NYSE American
Common Stock, $0.01 par value		UAMY		NYSE Texas

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On November 24, 2025, upon the recommendation of the Governance and Nominating Committee, the Board of Directors (the “Board”) of United States Antimony Corporation (NYSE: UAMY) (NYSE Texas: UAMY) (“USAC,” “US Antimony,” or the “Company”) appointed Jon R. Marinelli, to serve as a director of the Company, effective immediately. With Mr. Marinelli’s appointment, the USAC board size increases to seven members, five of which are Independent. Mr. Marinelli has also been appointed Chairman of a new board committee formed yesterday, the Finance Committee.

Mr. Marinelli is a seasoned financial executive and investment professional with more than 25 years of experience in capital markets, M&A, and strategic advisory roles, and has an early-career background in technology. He is the Founder and Principal of 1042 Capital Partners, where he manages public and private investments. Previously, he served as Group Head and Managing Director of U.S. Energy at BMO Capital Markets, and before that held senior roles in Deutsche Bank’s Global Banking–Natural Resources Group, the successor to Bankers Trust. Over his career, Mr. Marinelli has advised on more than $285 billion in M&A, public and private equity, and debt transactions. He holds an MBA from Rice University and a BS from Miami University.

Mr. Marinelli will serve until the Company’s next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal. There are no arrangements or understandings between Mr. Marinelli and any other person pursuant to which he was selected as a director, and there are no transactions involving Mr. Marinelli that are required to be disclosed under Item 404(a) of Regulation S-K.

Any compensation payable to Mr. Marinelli for his service as a director will be consistent with the Company’s previously disclosed standard compensation arrangements for non-employee directors.

Item 7.01 Regulation FD Disclosure.

On November 25, 2025, US Antimony issued a press release (“Press Release”) announcing the appointment of Jon R. Marinelli to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing. This Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as the materiality of any information in this Item 7.01 that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release issued by United States Antimony Corporation dated November 25, 2025
104		Cover Page Interactive Data File (embedded with the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED STATES ANTIMONY CORPORATION

Dated:	November 25, 2025		By:	/s/ Richard R. Isaak
			Richard R. Isaak
			SVP, Chief Financial Officer

FAQ

What did United States Antimony (UAMY) announce in this Form 8-K?

United States Antimony Corporation announced that its Board of Directors appointed Jon R. Marinelli as a new director, effective November 24, 2025, and created a new Finance Committee that he will chair.

How does Jon R. Marinelli’s appointment change UAMY’s board structure?

With Jon R. Marinelli’s appointment, UAMY’s Board now has seven members, including five independent directors, and a new Finance Committee chaired by Marinelli.

What is Jon R. Marinelli’s professional background relevant to UAMY?

Jon R. Marinelli is a seasoned financial executive with more than 25 years of experience in capital markets, M&A, and strategic advisory, and has advised on over $285 billion in M&A, equity, and debt transactions.

How long will Jon R. Marinelli serve on the United States Antimony board?

Jon R. Marinelli will serve as a director until UAMY’s next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal.

Are there any related-party transactions between UAMY and Jon R. Marinelli?

The company states there are no arrangements or understandings with any other person under which Marinelli was selected and no transactions involving him that must be disclosed under Item 404(a) of Regulation S-K.

How will Jon R. Marinelli be compensated for his role at UAMY?

Any compensation payable to Jon R. Marinelli for his service as a director will follow UAMY’s previously disclosed standard compensation arrangements for non-employee directors.

Did United States Antimony issue a press release about this board appointment?

Yes. On November 25, 2025, UAMY issued a press release announcing Jon R. Marinelli’s appointment to the Board, which is furnished as Exhibit 99.1 to this Form 8-K.